Vera Therapeutics (VERA) Stock Forecast & Price Target

Vera Therapeutics is supported by a mechanistically compelling asset in atacicept, which blocks both B lymphocyte stimulator and APRIL to reduce autoantibody-driven immune activity in serious immunological disease. The provided data suggest that kidney function stabilization is a meaningful signal, as Trutakna’s eGFR changes appear similar to Voyxact’s +5.5 ml/min improvement through 12 months and +9.2 ml/min improvement at 24 months, reinforcing the role of APRIL in IgAN. Commercially, the expanding IgAN market and Otsuka’s early launch traction of 180, 880, and 960 patient start forms, plus guidance for over ¥100B by 2027, support a favorable backdrop while VERA awaits ORIGIN3 data in 3Q26.

Vera Therapeutics is facing a weak fundamental setup because atacicept remains dependent on regulatory outcomes that may require additional data, longer studies, or narrower labels, all of which could delay adoption and restrict commercial traction. Financially, the company reported no revenue in 2Q26 and a net loss of $1.52 per share, while projected 2026 revenue is only $16M alongside a $6.52 diluted EPS loss, underscoring that meaningful earnings power remains distant. Although cash of about $499M may fund operations through potential approval and U.S. launch, the need for additional financing, dilution risk, and cautious launch assumptions versus competitors support a negative outlook.